P. O'dwyer

发表

Cellular kinetics of induction by oltipraz and its keto derivative of detoxication enzymes in human colon adenocarcinoma cells.

P. O'dwyer, M. Clayton, T. Halbherr, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

Effects of geldanamycin on signaling through activator-protein 1 in hypoxic HT29 human colon adenocarcinoma cells.

P. O'dwyer, I. Vasilevskaya, Peter J. O’Dwyer, 1999, Cancer research.

Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.

K. Flaherty, R. Kurzrock, N. Le, 2012, The Lancet. Oncology.

Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer

P. Gibbs, J. Desai, J. Issa, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Inhibition of mutated, activated BRAF in metastatic melanoma.

K. Flaherty, J. Sosman, A. Ribas, 2010, The New England journal of medicine.

Clinical Pharmacokinetics and Administration of Established Platinum Drugs

Steven W. Johnson, P. O'dwyer, J. Stevenson, 2012, Drugs.

Gene expression patterns in ovarian carcinomas.

Trevor Hastie, Robert Tibshirani, David Botstein, 2003, Molecular biology of the cell.

Phase I clinical trial design in cancer drug development.

M. Christian, E. Eisenhauer, P. O'dwyer, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I Cl inica l Tria l Des ign in Cancer Drug Development

M. Christian, E. Eisenhauer, P. O'dwyer, 2000 .

Phase II Clinical Trials in Oncology

P. O'dwyer, J. Gallo, A. Rogatko, 1997 .

Time-dependent pharmacodynamic models in cancer chemotherapy: population pharmacodynamic model for glutathione depletion following modulation by buthionine sulfoximine (BSO) in a Phase I trial of melphalan and BSO.

R. Ozols, P. O'dwyer, T. Halbherr, 1995, Cancer research.

Guidelines for the use and interpretation of assays formonitoring autophagy (3rd edition)

Sangeeta Khare, Xin Qi, Ying Wang, 2016 .

Antiangiogenic tyrosine kinase inhibitors in colorectal cancer: is there a path to making them more effective?

M. Rosen, P. O'dwyer, T. Karasic, 2017, Cancer Chemotherapy and Pharmacology.

Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study

K. Flaherty, M. Rosen, P. O'dwyer, 2011, Cancer Chemotherapy and Pharmacology.

A Phase I Trial of the Oral, Multikinase Inhibitor Sorafenib in Combination with Carboplatin and Paclitaxel

D. Elder, K. Flaherty, B. Weber, 2008, Clinical Cancer Research.

Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma

K. Flaherty, P. O'dwyer, B. Schwartz, 2008, Cancer biology & therapy.

Phase II trial of sorafenib in advanced thyroid cancer.

Andrea B Troxel, Keith T Flaherty, K. Flaherty, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical studies of reversal of drug resistance based on glutathione.

P. O'dwyer, K. Yao, T. Hamilton, 1998, Chemico-biological interactions.

Phase II study of elsamitrucin (BMY-28090) for the treatment of patients with refractory/relapsed non-Hodgkin's lymphoma

P. O'dwyer, R. Bukowski, M. Hensley, 2004, Investigational New Drugs.

Thymidylate synthase protein expression in primary colorectal cancer: lack of correlation with outcome and response to fluorouracil in metastatic disease sites.

P. Catalano, P. Johnston, A. Benson, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans

Drew A. Torigian, Babak Saboury, Dongguang Li, 2011, Science.

Clinical study of genomic drivers in pancreatic ductal adenocarcinoma

E. Lenkiewicz, V. Velculescu, M. Barrett, 2017, British Journal of Cancer.

A Phase I Study of an Agonist CD40 Monoclonal Antibody (CP-870,893) in Combination with Gemcitabine in Patients with Advanced Pancreatic Ductal Adenocarcinoma

A. Alavi, D. Torigian, A. Troxel, 2013, Clinical Cancer Research.

Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody.

K. Flaherty, P. O'dwyer, S. Antonia, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Modulation of gene expression in subjects at risk for colorectal cancer by the chemopreventive dithiolethione oltipraz.

P. Engstrom, S. Litwin, P. O'dwyer, 1996, The Journal of clinical investigation.

Apoptosis in human adenocarcinoma HT29 cells induced by exposure to hypoxia.

P. O'dwyer, M. Clayton, K. Yao, 1995, Journal of the National Cancer Institute.

Phase I Trial of Combretastatin A-4 Phosphate with Carboplatin

K. Flaherty, M. Rosen, M. Schnall, 2005, Clinical Cancer Research.

Hypersensitivity reactions induced by etoposide.

P. O'dwyer, R. Weiss, 1984, Cancer treatment reports.

Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer.

R. Herbst, R. Kurzrock, A. Jubb, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Apo2L/TRAIL pharmacokinetics in a phase 1a trial in advanced cancer and lymphoma.

R. Herbst, P. O'dwyer, G. Lieberman, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I safety and pharmacokinetic (PK) study of recombinant Apo2L/TRAIL, an apoptosis-inducing protein in patients with advanced cancer.

R. Herbst, R. Kurzrock, W. Novotny, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I trial of the novel taxane BMS-184476 administered in combination with carboplatin every 21 days

P. O'dwyer, D. Vaughn, J. Stevenson, 2004, British Journal of Cancer.

Inhibition of G1/S transition potentiates oxaliplatin-induced cell death in colon cancer cell lines.

P. O'dwyer, I. Vasilevskaya, Tatiana V Rakitina, 2007, Biochemical pharmacology.

TNF Signaling through RIP1 Kinase Enhances SN38-Induced Death in Colon Adenocarcinoma

P. O'dwyer, Lucía Cabal-Hierro, 2017, Molecular Cancer Research.

JNK1 Inhibition Attenuates Hypoxia-Induced Autophagy and Sensitizes to Chemotherapy

P. O'dwyer, M. Selvakumaran, I. Vasilevskaya, 2016, Molecular Cancer Research.

Autophagy Inhibition Sensitizes Colon Cancer Cells to Antiangiogenic and Cytotoxic Therapy

P. O'dwyer, M. Selvakumaran, I. Vasilevskaya, 2013, Clinical Cancer Research.

Additive interaction of oxaliplatin and 17-allylamino-17-demethoxygeldanamycin in colon cancer cell lines results from inhibition of nuclear factor kappaB signaling.

P. O'dwyer, I. Vasilevskaya, T. Rakitina, 2003, Cancer research.

Glutathione and drug resistance.

R. Ozols, A. Godwin, K. Tew, 1996, Cancer investigation.

Spiromustine: a new agent entering clinical trials

S. Marsoni, P. O'dwyer, J. Plowman, 2004, Investigational New Drugs.

Safety and Efficacy Results of a Phase I, Open-Label Study of Concurrent and Delayed Nivolumab in Combination With nab-Paclitaxel and Carboplatin in Advanced Non-small Cell Lung Cancer

K. Kelly, P. O'dwyer, J. Goldman, 2019, Front. Oncol..

Modulation of glutathione and related enzymes in reversal of resistance to anticancer drugs.

R. Ozols, K. Tew, P. O'dwyer, 1995, Hematology/oncology clinics of North America.

Current Activities of the Coalition of Cancer Cooperative Groups.

W. Curran, M. Schnall, M. Bertagnolli, 2018, Journal of the National Cancer Institute.

Rhabdomyolysis from cytochrome p-450 interaction of ketoconazole and simvastatin in prostate cancer.

D. Haller, P. O'dwyer, D. Vaughn, 2003, The Journal of urology.

Dielectrophoretic Capture and Genetic Analysis of Single Neuroblastoma Tumor Cells

E. Rappaport, P. O'dwyer, Y. Mossé, 2014, Front. Oncol..

Race, treatment preferences, and hospice enrollment: Eligibility criteria may exclude patients with the greatest needs for care

D. Asch, P. O'dwyer, D. Casarett, 2009, Cancer.

Phase 2 trial of bevacizumab, capecitabine, and oxaliplatin in treatment of advanced hepatocellular carcinoma

M. Rosen, M. Soulen, D. Haller, 2011, Cancer.

How should we design supportive cancer care? The patient's perspective.

D. Asch, M. Naylor, F. Barg, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect of time interval between surgery and preoperative chemoradiotherapy with 5‐fluorouracil or 5‐fluorouracil and oxaliplatin on outcomes in rectal cancer

E. Rosato, J. Metz, L. Solin, 2007, Journal of surgical oncology.

Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy.

P. O'dwyer, R. Catalano, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Irinotecan and UFT/leucovorin in patients with advanced cancers.

D. Haller, P. O'dwyer, J. Stevenson, 2000, Oncology.

High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200

P. Catalano, A. Benson, S. Alberts, 2005 .

Eastern Cooperative Oncology Group phase II trial (E4296) of oral 5-fluorouracil and eniluracil as a 28-day regimen in metastatic colorectal cancer.

P. Catalano, A. Benson, M. Cornfeld, 2002, Clinical colorectal cancer.

Current status of oxaliplatin in colorectal cancer.

Steven W. Johnson, P. O'dwyer, 2003, Seminars in oncology.

Determination of the platinum drug cis-amminedichloro(2-methylpyridine)platinum(II) in human urine by liquid chromatography-tandem mass spectrometry.

D. Roberts, P. O'dwyer, I. Blair, 2003, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Epidermal growth factor receptor-targeted therapy in colorectal cancer.

A. Benson, P. O'dwyer, 2002, Seminars in oncology.

Phase II trial of topotecan as a 21-day continuous infusion in patients with advanced or metastatic adenocarcinoma of the pancreas.

P. O'dwyer, K. Yao, J. Stevenson, 1998, European journal of cancer.

Phase II study of biochemical modulation of fluorouracil by low-dose PALA in patients with colorectal cancer.

S. Litwin, L. Weiner, P. O'dwyer, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200.

P. Catalano, A. Benson, S. Alberts, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Predictive Biomarkers and Personalized Medicine Association betweenVEGFSplice IsoformsandProgression-Free Survival in Metastatic Colorectal Cancer Patients Treated with Bevacizumab

P. Catalano, S. Harper, D. Bates, 2012 .

A phase I and pharmacokinetic study of lapatinib in combination with infusional 5-fluorouracil, leucovorin and irinotecan.

D. Kerr, K. Flaherty, P. O'dwyer, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Biochemical modulation as an approach to reversal of antimetabolite resistance.

P. O'dwyer, 1994, Cancer treatment and research.

First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies

P. O'dwyer, P. Scherle, T. Gajewski, 2017, Clinical Cancer Research.

Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV.

I. Hyodo, J. Abbruzzese, S. Wadler, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Antitumor effect of the angiogenesis inhibitor bevacizumab is dependent on susceptibility of tumors to hypoxia-induced apoptosis.

M. Feldman, P. O'dwyer, K. Yao, 2008, Biochemical pharmacology.

Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q.

S. Luoh, R. Gray, K. Flaherty, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Combined MTOR and autophagy inhibition

A. Alavi, D. Torigian, A. Troxel, 2014, Autophagy.

Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer

K. Flaherty, K. Wilner, A. DeMichele, 2011, Clinical Cancer Research.

Phase I and pharmacokinetic trial of the proapoptotic sulindac analog CP-461 in patients with advanced cancer.

D. Haller, P. O'dwyer, J. Gallo, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Expression in HT 29 Colon Adenocarcinoma Cells Effects of Hypoxia on Detoxicating Enzyme Activity and Updated

A. Godwin, P. O'dwyer, M. Clayton, 2006 .

Phase I trial of tirapazamine in combination with cisplatin in a single dose every 3 weeks in patients with solid tumors.

P. O'dwyer, C. Langer, M. Graham, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effects of hypoxia on detoxicating enzyme activity and expression in HT29 colon adenocarcinoma cells.

A. Godwin, P. O'dwyer, M. Clayton, 1994, Cancer research.

A phase I, dose escalation trial of ZD0473, a novel platinum analogue, in combination with gemcitabine

K. Flaherty, P. O'dwyer, J. Stevenson, 2004, Cancer Chemotherapy and Pharmacology.

Dose escalation study of tezacitabine in combination with cisplatin in patients with advanced cancer

K. Flaherty, D. Haller, P. O'dwyer, 2003, Cancer.

Final findings from a phase II, placebo-controlled, randomized discontinuation trial (RDT) of sorafenib (BAY 43–9006) in patients with advanced renal cell carcinoma (RCC)

M. Ratain, K. Flaherty, M. Gore, 2005 .

Identification of genes associated with platinum drug sensitivity and resistance in human ovarian cancer cells

P B Laub, S. Conway, P. O'dwyer, 2005, British Journal of Cancer.

Involvement of NF-κB in the induction of NAD(P)H: Quinone oxidoreductase (DT-diaphorase) by hypoxia, oltipraz and mitomycin C

P. O'dwyer, K. Yao, 1995 .

Activation of AP-1 and of a nuclear redox factor, Ref-1, in the response of HT29 colon cancer cells to hypoxia.

T. Curran, P. O'dwyer, K. Yao, 1994, Molecular and cellular biology.

The chemopreventive agent oltipraz stimulates repair of damaged DNA.

A. Krueger, P. O'dwyer, K. Yao, 1997, Cancer research.

Gefitinib in advanced unresectable hepatocellular carcinoma: Results from the Eastern Cooperative Oncology Group's Study E1203.

A. Benson, P. O'dwyer, J. Kauh, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I/II trial of BAY 43-9006, carboplatin (C) and paclitaxel (P) demonstrates preliminary antitumor activity in the expansion cohort of patients with metastatic melanoma.

K. Flaherty, D. Tuveson, B. Weber, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) Results of Protocol E1293

D. Neuberg, A. Benson, P. O'dwyer, 1996, Medical oncology.

Carboplatin and paclitaxel in ovarian carcinoma: a phase I study of the Gynecologic Oncology Group.

R. Ozols, P. O'dwyer, S. Johnson, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Strong Signature of Natural Selection within an FHIT Intron Implicated in Prostate Cancer Risk

Guillermo E. Rivas, A. Benson, J. Stewart, 2008, PloS one.

Characterization of Neutropenia in Advanced Cancer Patients Following Palbociclib Treatment Using a Population Pharmacokinetic‐Pharmacodynamic Modeling and Simulation Approach

G. Shapiro, A. DeMichele, G. Schwartz, 2017, Journal of clinical pharmacology.

Pharmacodynamic assessment of INCB024360, an inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1), in advanced cancer patients.

P. O'dwyer, P. Scherle, T. Gajewski, 2012 .

Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the oral inhibitor of indoleamine 2,3-dioxygenase (IDO1) INCB024360 in patients (pts) with advanced malignancies.

P. O'dwyer, T. Gajewski, L. Leopold, 2013 .

Epidermal growth factor receptor-targeted therapy in colorectal cancer.

A. Benson, P. O'dwyer, 2002, Seminars in oncology.

Effects of Hypoxiaon DetoxicatingEnzymeActivity and Expressionin HT29 Colon Adenocarcinoma Cells

A. Godwin, P. O'dwyer, M. Clayton, 1994 .

Phase II Trial of Palbociclib in Patients with Advanced Esophageal or Gastric Cancer.

P. O'dwyer, M. O'Hara, Paul J. L. Zhang, 2018, The oncologist.

Role of the AP-1 element and redox factor-1 (Ref-1) in mediating transcriptional induction of DT-diaphorase gene expression by oltipraz: a target for chemoprevention.

P. O'dwyer, K. Yao, 2003, Biochemical pharmacology.

Hypersensitivity reactions to teniposide (VM-26): an analysis.

B. Leyland-Jones, P. O'dwyer, S. A. King, 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

SR2508 (etanidazole) pharmacokinetics and biochemical effects in tumor and normal tissues of scid mice bearing HT-29 human colon adenocarcinoma.

P. O'dwyer, F. LaCreta, L. Panting, 1993, Biochemical pharmacology.

High-performance liquid chromatographic determination of ethacrynic acid in human plasma.

P. O'dwyer, F. LaCreta, J. Brennan, 1991, Journal of chromatography.

Evaluation of the long term outcome of patients with extremity desmoids.

P. O'dwyer, R. Reid, C. Chew, 2004, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Biochemistry and clinical activity of N-(phosphonacetyl)-L-aspartate: a review.

B. Leyland-Jones, J. Grem, P. O'dwyer, 1988, Cancer research.

Comparing the clinical impact of pancreatic cyst surveillance programs: A trial of the ECOG-ACRIN cancer research group (EA2185).

C. Gatsonis, P. O'dwyer, H. Zeh, 2020, Contemporary clinical trials.

Sorafenib combined with carboplatin/paclitaxel for advanced non-small cell lung cancer: A phase I subset analysis.

K. Flaherty, J. Schiller, P. O'dwyer, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High rate of consent to bank biologic samples for future research: the Eastern Cooperative Oncology Group experience.

P. Catalano, P. O'dwyer, B. Giantonio, 2002, Journal of the National Cancer Institute.

Activation of AP-1 and of a nuclear redox factor, Ref-1, in the response of HT29 colon cancer cells to hypoxia

T. Curran, P. O'dwyer, K. Yao, 1994 .

MacrophageMigration Inhibitory Factor Is a Determinant of Hypoxia-Induced Apoptosis in Colon Cancer Cell

Steven W. Johnson, P. O'dwyer, M. Selvakumaran, 2005 .

Depletion of glutathione in normal and malignant human cells in vivo by buthionine sulfoximine: clinical and biochemical results.

R. Ozols, K. Tew, P. O'dwyer, 1992, Journal of the National Cancer Institute.

A phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancer

J. Berlin, J. Shults, D. Haller, 2005, British Journal of Cancer.

Pharmacodynamic study of BAY 43-9006 in patients with metastatic renal cell carcinoma

K. Flaherty, M. Rosen, P. O'dwyer, 2005 .

Changes in the concentrations of plasma selenium and selenoproteins after minor elective surgery: further evidence for a negative acute phase response?

D. Littlejohn, P. O'dwyer, N. Sattar, 1998, Clinical chemistry.

Abstract CT014: GSK525762, a selective bromodomain (BRD) and extra terminal protein (BET) inhibitor: results from part 1 of a phase I/II open-label single-agent study in patients with NUT midline carcinoma (NMC) and other cancers

G. Shapiro, R. Prinjha, S. Piha-Paul, 2016 .

Abstract CT101: NCI-molecular analysis for therapy choice (NCI-MATCH) clinical trial: interim analysis

R. Gray, K. Flaherty, L. Rubinstein, 2016 .

Phase I/II, pharmacokinetic and pharmacodynamic trial of BAY 43–9006 alone in patients with metastatic melanoma

K. Flaherty, B. Weber, P. O'dwyer, 2005 .

Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma.

G. Rosner, M. Ratain, K. Flaherty, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours

Robin L. Jones, C. Rudin, M. Ratain, 2019, European journal of cancer.

Updated results of a randomized phase II study comparing two schedules of temozolomide in combination with sorafenib in patients with advanced melanoma

K. Flaherty, A. Troxel, K. Nathanson, 2006 .

Preliminary results of a randomized phase II study comparing two schedules of temozolomide in combination with sorafenib in patients with advanced melanoma.

K. Flaherty, D. Tuveson, A. Troxel, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Brivanib (B) in Advanced Ovarian Cancer (OC): Subset Results of a Phase 2 Randomized Discontinuation Trial (RDT)

C. Rudin, M. Ratain, G. Schwartz, 2012 .

Brivanib (BMS-582664) in advanced soft-tissue sarcoma (STS): Biomarker and subset results of a phase II randomized discontinuation trial.

C. Rudin, M. Ratain, M. Sawyer, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Brivanib (BMS-582664) in advanced solid tumors (AST): Results of a phase II randomized discontinuation trial (RDT).

C. Rudin, M. Ratain, A. Oza, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines.

R. Ozols, A. Godwin, P. O'dwyer, 1993, Cancer research.

A validated liquid chromatography/tandem mass spectrometry assay for cis-amminedichloro(2-methylpyridine)platinum(II) in human plasma ultrafiltrate.

D. Roberts, P. O'dwyer, I. Blair, 2002, Analytical chemistry.

Pharmacodynamic study of the raf kinase inhibitor BAY 43-9006: Mechanisms of hypertension.

K. Flaherty, M. Rosen, P. O'dwyer, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of bevacizumab dose reduction on clinical outcomes for patients treated on the Eastern Cooperative Oncology Group's Study E3200.

P. Catalano, A. Benson, P. O'dwyer, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Evidence for altered regulation of gamma-glutamylcysteine synthetase gene expression among cisplatin-sensitive and cisplatin-resistant human ovarian cancer cell lines.

R. Ozols, A. Godwin, P. O'dwyer, 1995, Cancer research.

Drug resistance in ovarian cancer and potential for its reversal

Steven W. Johnson, R. Ozols, A. Godwin, 1995 .

A phase I trial of topotecan and gemcitabine administered weekly for 3 consecutive weeks to patients with advanced tumors

D. Haller, P. O'dwyer, D. Vaughn, 2001, Cancer.

Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer.

Gary Middleton, Takayuki Yoshino, Chloe E Atreya, 2018, Cancer discovery.

Fluoropyrimidine (FP) + bevacizumab (BEV) + atezolizumab vs FP/BEV in BRAFwt metastatic colorectal cancer (mCRC): Findings from Cohort 2 of MODUL - a multicentre, randomized trial of biomarker-driven maintenance treatment following first-line induction therapy.

E. Van Cutsem, M. Ducreux, J. Tabernero, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

The next generation of targeted therapy trials in colorectal cancer.

P. O'dwyer, 2014, Clinical advances in hematology & oncology : H&O.

Phase II study of sorafenib and docetaxel in men with metastatic castration resistant prostate cancer (mCRPC).

G. Adluru, K. Flaherty, A. Troxel, 2009, Journal of Clinical Oncology.

612TiPMODUL-A MULTICENTRE RANDOMISED CLINICAL TRIAL OF BIOMARKER-DRIVEN THERAPY FOR THE 1ST-LINE MAINTENANCE TREATMENT OF METASTATIC COLORECTAL CANCER (MCRC): A SIGNAL-SEEKING APPROACH.

E. Van Cutsem, M. Ducreux, J. Tabernero, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

LBA-07Updated Results of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal cancer (mCRC)

C. Atreya, M. Ducreux, J. Schellens, 2015 .

FOENIX-101: A phase II trial of TAS-120 in patients with intrahepatic cholangiocarcinoma harboring FGFR2 gene rearrangements.

M. Borad, J. Furuse, H. Chang, 2019, Journal of Clinical Oncology.

A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: A trial of the ECOG-ACRIN Cancer Research Group (E2211).

P. Catalano, A. Benson, James C Yao, 2015 .

Cisplatin Resistance in Ovarian Cancer Cell Lines Cross-Resistance to Diverse Drugs Is Associated with Primary Updated Version

Thomas, Yakushiji, R. Ozols, 2006 .

The role of glutathione in drug resistance.

R. Ozols, P. O'dwyer, T. Hamilton, 1990, Cancer treatment reviews.

Platinum Complexes for the Treatment of Cancer

Steven W. Johnson, P. O'dwyer, David A. Roberts, 2011 .

High-performance liquid chromatographic determination of the S- and R-diastereoisomers of L-buthionine (SR)-sulfoximine in human plasma and urine.

R. Ozols, P. O'dwyer, F. LaCreta, 1993, Journal of chromatography.

Variable baseline gamma-glutamylcysteine synthetase messenger RNA expression in peripheral mononuclear cells of cancer patients, and its induction by buthionine sulfoximine treatment.

R. Ozols, A. Godwin, P. O'dwyer, 1993, Cancer research.

Interaction of heat and hypoxia in modulating transcription of DT diaphorase in human colon adenocarcinoma cells.

P. O'dwyer, M. Clayton, K. Yao, 1994, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

Phase I trial of buthionine sulfoximine (BSO) in combination with melphalan

R. Ozols, P. O'dwyer, T. Hamilton, 1993 .

Phase III trial of gemcitabine (30-minute infusion) versus gemcitabine (fixed-dose-rate infusion [FDR]) versus gemcitabine + oxaliplatin (GEMOX) in patients with advanced pancreatic cancer (E6201).

J. Berlin, D. Cella, A. Benson, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cyclin-Dependent Kinase 4/6 Inhibition for the Treatment of Unresectable Mature Teratoma: Long-Term Follow-Up of a Phase II Study.

M. Rosen, W. Hwang, P. O'dwyer, 2016, Clinical genitourinary cancer.

Phase I pharmacokinetic study of intraperitoneal etoposide.

P. O'dwyer, N. Rosenblum, F. LaCreta, 1991, Cancer research.

Clinical Aspects of FUra Metabolism

B. Leyland-Jones, P. O'dwyer, 1986 .

Pharmacology and clinical investigation of SR-2508 (etanidazole).

P. O'dwyer, F. LaCreta, 1991, Cancer treatment and research.

A phase II trial of edatrexate in patients with advanced renal cell carcinoma. An Eastern Cooperative Oncology Group study.

J. Kirkwood, K. Propert, T. Kuzel, 1997, American journal of clinical oncology.

Biochemical modulation: application of laboratory models to the clinic.

B. Leyland-Jones, P. O'dwyer, O'Dwyer Pj, 1986, Cancer treatment reports.

Antisense therapeutics: lessons from early clinical trials

K. Flaherty, P. O'dwyer, J. Stevenson, 2001, Current opinion in oncology.

Management of soft tissue sarcomas of the abdomen and pelvis

A. Barrett, P. O'dwyer, R. Reid, 2003, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

Antitumor activity and biochemical effects of aphidicolin glycinate (NSC 303812) alone and in combination with cisplatin in vivo.

P. O'dwyer, J. Plowman, T. Hamilton, 1994, Cancer research.

A Phase I Study of GGTI-2418 (Geranylgeranyl Transferase I Inhibitor) in Patients with Advanced Solid Tumors

S. Sebti, P. O'dwyer, E. Chiorean, 2019, Targeted Oncology.

Phase I/II: The oral isotype-selective HDAC inhibitor MGCD0103 in combination with gemcitabine (Gem) in patients (pts) with refractory solid tumors

H. Hurwitz, E. Chan, B. Nelson, 2007 .

Tumor Genomic Profiling Practices and Perceptions: A Survey of Physicians Participating in the NCI-MATCH Trial.

K. Flaherty, A. Chen, B. Conley, 2020, JCO precision oncology.

A phase I dose escalation trial of a daily oral CDK 4/6 inhibitor PD-0332991

K. Wilner, A. DeMichele, P. LoRusso, 2007 .

Do phase 1 patients have greater needs for palliative care compared with other cancer patients?

P. O'dwyer, Esmé Finlay, D. Casarett, 2009, Cancer.

17-Allylamino-17-demethoxygeldanamycin overcomes TRAIL resistance in colon cancer cell lines.

P. O'dwyer, I. Vasilevskaya, 2005, Biochemical pharmacology.

Phase I Trial of Regorafenib, Hydroxychloroquine, and Entinostat in Metastatic Colorectal Cancer

P. O'dwyer, K. Reiss, M. O'Hara, 2021, The oncologist.

A phase II study of vismodegib, a hedgehog (Hh) pathway inhibitor, combined with gemcitabine and nab-paclitaxel (nab-P) in patients (pts) with untreated metastatic pancreatic ductal adenocarcinoma (PDA).

A. Maitra, V. Bolejack, P. O'dwyer, 2014 .

Treatment of early stage Hodgkin’s disease: A randomized trial of radiotherapy plus chemotherapy versus chemotherapy alone

P. O'dwyer, P. Wiernik, R. Slawson, 1985 .

Phase I study of nivolumab (Nivo) + nab-paclitaxel (nab-P) + gemcitabine (Gem) in advanced pancreatic cancer (APC).

Edward J. Kim, Z. Wainberg, P. O'dwyer, 2019, Journal of Clinical Oncology.

Phase I trial of thiotepa in combination with recombinant human granulocyte-macrophage colony-stimulating factor.

R. Ozols, P. O'dwyer, G. Hudes, 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Preservation of immune effector cell function following administration of a dose-intense 5-fluorouracil-chemotherapy regimen

S. Litwin, L. Weiner, P. O'dwyer, 2005, Cancer Immunology, Immunotherapy.

First use of an oral Hsp90 inhibitor in patients (Pts) with solid tumors: Alvespimycin (A) administered QOD or Q

K. Flaherty, P. O'dwyer, A. Hannah, 2008 .

Abstract CT234: A Phase II, single arm study of maintenance rucaparib in patients with platinum-sensitive advanced pancreatic cancer and a pathogenic germline or somatic mutation inBRCA1, BRCA2orPALB2

D. Mankoff, K. Nathanson, S. Domchek, 2019, Clinical Trials.

Overview of phase II trials of MTA in solid tumors.

P. O'dwyer, D. Thornton, K. Nelson, 1999, Seminars in oncology.

Differential gene expression patterns and interaction networks in BCR-ABL-positive and -negative adult acute lymphoblastic leukemias.

Dejan Juric, D. Juric, B. Sikic, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of topotecan in advanced or metastatic adenocarcinoma of the pancreas

P. Engstrom, P. O'dwyer, K. Amfoh, 1995, Investigational New Drugs.

Preliminary evaluation of response to combination of RAD001 and cetuximab using [18F]-fluorodeoxyglucose positron emission tomography (18FDG-PET)

K. Flaherty, P. O'dwyer, C. Divgi, 2008 .

A phase II trial of gefitinib in combination with 5-FU/LV/irinotecan in patients with colorectal cancer.

K. Flaherty, D. Haller, P. O'dwyer, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Involvement of NF-kappa B in the induction of NAD(P)H:quinone oxidoreductase (DT-diaphorase) by hypoxia, oltipraz and mitomycin C.

P. O'dwyer, K. Yao, 1995, Biochemical pharmacology.

Phase II Trials

K. Flaherty, P. O'dwyer, 2004 .

Etoposide (VP-16-213). Current status of an active anticancer drug.

R. Wittes, B. Leyland-Jones, S. Marsoni, 1985, The New England journal of medicine.

Homoharringtonine--perspectives on an active new natural product.

B. Leyland-Jones, P. O'dwyer, M. Suffness, 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract CT165: Phase II open label trial of minnelide™ in patients with chemotherapy refractory metastatic pancreatic cancer

G. Evan, T. Littlewood, R. Evans, 2019, Clinical Trials.

High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis.

A. Godwin, M. Anderson, P. O'dwyer, 1992, Proceedings of the National Academy of Sciences of the United States of America.

2'-Deoxycoformycin (pentostatin) for lymphoid malignancies. Rational development of an active new drug.

R. Wittes, B. Cheson, B. Leyland-Jones, 1988, Annals of internal medicine.

The clinical horizon of deoxycoformycin

B. Leyland-Jones, P. O'dwyer, D. Hoth, 1987 .

Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow.

Weijing Sun, Daniel G Haller, Mark Rosen, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma

A. Troxel, D. Heitjan, K. Nathanson, 2014, Autophagy.

Phase I/pharmacokinetic study of the topoisomerase I inhibitor GG211 administered as a 21-day continuous infusion.

L. Grochow, L. Paz-Ares, P. O'dwyer, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

The role of low-dose PALA in biochemical modulation.

P. O'dwyer, 1990, Pharmacology & therapeutics.

Vitamin D Receptor-Mediated Stromal Reprogramming Suppresses Pancreatitis and Enhances Pancreatic Cancer Therapy

G. Wahl, E. Collisson, D. Tuveson, 2014, Cell.

Open-label, Phase I Study of Nivolumab Combined with nab-Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer

Edward J. Kim, David J. Reiss, Z. Wainberg, 2020, Clinical Cancer Research.

Phase I trial of N-methylformamide (NMF, NSC 3051).

P. O'dwyer, D. V. Van Echo, J. Aisner, 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect of Gemcitabine and nab-Paclitaxel With or Without Hydroxychloroquine on Patients With Advanced Pancreatic Cancer: A Phase 2 Randomized Clinical Trial.

D. V. Von Hoff, P. O'dwyer, K. Reiss, 2019, JAMA oncology.

A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma.

R. Wittes, R. Simon, R. Simon, 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Therapeutic synergism of tiazofurin and selected antitumor drugs against sensitive and resistant P388 leukemia in mice.

P. O'dwyer, M. Trader, S. Harrison, 1986, Cancer research.

Tiazofurin: A new antitumor agent

S. Marsoni, P. O'dwyer, J. Plowman, 2004, Investigational new drugs.

Fluorouracil modulation in colorectal cancer: lack of improvement with N -phosphonoacetyl- l -aspartic acid or oral leucovorin or interferon, but enhanced therapeutic index with weekly 24-hour infusion schedule--an Eastern Cooperative Oncology Group/Cancer and Leukemia Group B Study.

J. Manola, S. Arbuck, A. Benson, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I trial of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine riboside: optimization of 6-methylmercaptopurine riboside dose and schedule through biochemical analysis of sequential tumor biopsy specimens.

R. Ozols, P. O'dwyer, D. Martin, 1991, Journal of the National Cancer Institute.

Role of thymidine in biochemical modulation: a review.

B. Leyland-Jones, P. O'dwyer, D. Hoth, 1987, Cancer research.

2'-Deoxycoformycin: Summary and future directions

R. Wittes, S. Marsoni, P. O'dwyer, 1984 .

Phase I study of phosphonacetyl-l-aspartate, 5-fluorouracil, and leucovorin in patients with advanced cancer

R. Ozols, P. O'dwyer, G. Hudes, 2004, Cancer Chemotherapy and Pharmacology.

Involvement of activator protein-1 and nuclear factor-kappaB transcription factors in the control of the DT-diaphorase expression induced by mitomycin C treatment.

P. O'dwyer, P. Ford, K. Yao, 1997, Molecular pharmacology.

Increased DT-diaphorase expression and cross-resistance to mitomycin C in a series of cisplatin-resistant human ovarian cancer cell lines.

A. Godwin, R. Perez, P. O'dwyer, 1996, Biochemical pharmacology.

Phase I clinical/pharmacokinetic and pharmacodynamic trial of the c-raf-1 antisense oligonucleotide ISIS 5132 (CGP 69846A).

P. O'dwyer, K. Yao, B. Monia, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Hypersensitivity reactions to deoxycoformycin

E. Eisenhauer, J. Grem, P. O'dwyer, 2004, Cancer Chemotherapy and Pharmacology.

Phase I trial of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine ribonucleoside

R. Ozols, P. O'dwyer, J. Colofiore, 1995, Cancer Chemotherapy and Pharmacology.

Phase II trial of PALA and 6-methylmercaptopurine riboside (MMPR) in combination with 5-fluorouracil in advanced pancreatic cancer

L. Weiner, P. O'dwyer, J. Hoffman, 2004, Investigational New Drugs.

Phase I trial of fluorouracil modulation by n-phosphonacetyl-l-aspartate and 6-methylmercaptopurine ribonucleoside (MMPR), and leucovorin in patients with advanced cancer

P. O'dwyer, G. Hudes, F. LaCreta, 2004, Investigational New Drugs.

Chemotherapy of advanced colorectal cancer.

P. O'dwyer, J. Stevenson, James P. Stevenson, 1998, Cancer treatment and research.

Acivicin: a new glutamine antagonist in clinical trials.

B. Leyland-Jones, P. O'dwyer, M. T. Alonso, 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

c-raf-1 depletion and tumor responses in patients treated with the c-raf-1 antisense oligodeoxynucleotide ISIS 5132 (CGP 69846A).

P. O'dwyer, K. Yao, B. Monia, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase II trial of PALA in combination with 5-fluorouracil in advanced pancreatic cancer

R. Ozols, P. O'dwyer, P. Flynn, 2004, Cancer Chemotherapy and Pharmacology.

NF-κB Activation by the Chemopreventive Dithiolethione Oltipraz Is Exerted through Stimulation of MEKK3 Signaling*

P. O'dwyer, Peter J O'Dwyer, Chu Won Nho, 2004, Journal of Biological Chemistry.

High-performance liquid chromatographic analysis of N,N',N"-triethylenethiophosphoramide in human plasma.

P. O'dwyer, F. LaCreta, P. Tinsley, 1989, Journal of chromatography.

Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer.

R. Ozols, P. O'dwyer, T. Halbherr, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Epithelial to mesenchymal plasticity and differential response to therapies in pancreatic ductal adenocarcinoma

Linda T. Nieman, M. Lawrence, D. Haber, 2019, Proceedings of the National Academy of Sciences.

Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors

Jason Clark, K. Flaherty, G. Wilding, 2011, Cancer Chemotherapy and Pharmacology.

A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme

A. Troxel, D. Heitjan, S. Brem, 2014, Autophagy.

Adjuvant treatment of colorectal cancer at the turn of the century: European and US perspectives.

R. Labianca, P. O'dwyer, R Labianca, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation

K. Nathanson, M. Rosen, S. Domchek, 2019, British Journal of Cancer.

Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial

M. Ratain, K. Flaherty, I. Judson, 2011, Investigational New Drugs.

Pharmacokinetic analysis of irinotecan plus bevacizumab in patients with advanced solid tumors

S. Litwin, P. O'dwyer, A. Dorr, 2009, Cancer Chemotherapy and Pharmacology.

CDK 4/6 Inhibitor Palbociclib (PD0332991) in Rb+ Advanced Breast Cancer: Phase II Activity, Safety, and Predictive Biomarker Assessment

D. Heitjan, M. Feldman, M. Rosen, 2014, Clinical Cancer Research.

A phase I trial of palbociclib and paclitaxel in metastatic breast cancer.

D. Heitjan, M. Feldman, M. Rosen, 2014 .

Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1)

K. Wilner, P. LoRusso, G. Schwartz, 2011, British Journal of Cancer.

Palbociclib (PD0332991)-a Selective and Potent Cyclin-Dependent Kinase Inhibitor: A Review of Pharmacodynamics and Clinical Development.

M. Feldman, A. DeMichele, P. O'dwyer, 2016, JAMA oncology.

A risk variant in an miR-125b binding site in BMPR1B is associated with breast cancer pathogenesis.

David Smith, Rebecca Sutphen, John J Rossi, 2009, Cancer research.

Molecular Triage Trials in Colorectal Cancer

P. O'dwyer, M. O'Hara, S. Hamilton, 2016, Cancer journal.

Inhibition of JNK Sensitizes Hypoxic Colon Cancer Cells to DNA-Damaging Agents

J. Winkler, P. O'dwyer, M. Selvakumaran, 2015, Clinical Cancer Research.

Pharmacokinetics and bioequivalence of etoposide following intravenous administration of etoposide phosphate and etoposide in patients with solid tumors.

P. O'dwyer, R. Bukowski, G. Goss, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Genetic linkage of prostate cancer risk to the chromosome 3 region bearing FHIT.

Guillermo E. Rivas, R. Elston, D. Neuberg, 2005, Cancer research.

Differential Outcomes in Codon 12/13 and Codon 61 NRAS-Mutated Cancers in the Phase II NCI-MATCH Trial of Binimetinib in Patients with NRAS-Mutated Tumors

R. Gray, K. Flaherty, L. Rubinstein, 2021, Clinical Cancer Research.

Ado-trastuzumab emtansine (T-DM1) in patients with HER2 amplified tumors excluding breast and gastric/gastro-esophageal junction (GEJ) adenocarcinomas: Results from the NCI-MATCH Trial (EAY131) Sub-protocol Q.

S. Luoh, R. Gray, K. Flaherty, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody.

K. Flaherty, P. O'dwyer, S. Green, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis

M. Ratain, K. Flaherty, M. Gore, 2006, British Journal of Cancer.

In vitro hypoxia-conditioned colon cancer cell lines derived from HCT116 and HT29 exhibit altered apoptosis susceptibility and a more angiogenic profile in vivo

J. Testa, P. O'dwyer, K. Yao, 2005, British Journal of Cancer.

Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients

R. Scharpf, V. Velculescu, Siân Jones, 2015, Nature Communications.

NCI-Molecular Analysis for Therapy Choice (NCI-MATCH) trial: A novel public-private partnership

Robert Gray, Carlos L. Arteaga, Lisa M. McShane, 2016 .

Nivolumab Is Effective in Mismatch Repair-Deficient Noncolorectal Cancers: Results From Arm Z1D-A Subprotocol of the NCI-MATCH (EAY131) Study.

R. Gray, K. Flaherty, L. Rubinstein, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

BRAF-Mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer

J. Millholland, C. Atreya, E. Van Cutsem, 2020, Clinical Cancer Research.

Gene expression profiling of human ovarian tumours

V. Livolsi, P. O'dwyer, E. Sage, 2006, British Journal of Cancer.

Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group.

P. Catalano, J. Berlin, D. Cella, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors.

J. Desai, L. Saltz, S. Kopetz, 2010 .

Trametinib Activity in Patients with Solid Tumors and Lymphomas Harboring BRAF Non-V600 Mutations or Fusions: Results from NCI-MATCH (EAY131)

R. Gray, K. Flaherty, L. Rubinstein, 2020, Clinical Cancer Research.

Macrophage Migration Inhibitory Factor Is a Determinant of Hypoxia-Induced Apoptosis in Colon Cancer Cell Lines

Steven W. Johnson, P. O'dwyer, K. Yao, 2005, Clinical Cancer Research.

Markers in Colorectal Cancer and Clinical Trials Based Upon Them

P. O'dwyer, M. O'Hara, 2015, Current Colorectal Cancer Reports.

Association between DNA Methylation and Shortened Survival in Patients with Advanced Colorectal Cancer Treated with 5-Fluorouracil–Based Chemotherapy

P. Catalano, A. Benson, J. Issa, 2007, Clinical Cancer Research.

The Clinical Development of Lurtotecan

K. Flaherty, P. O'dwyer, C. Twelves, 2005 .

Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma

A. Maitra, D. V. Von Hoff, E. Sugar, 2019, British Journal of Cancer.

Dynamic Contrast-enhanced MRI Detects Responses to Stroma-directed Therapy in Mouse Models of Pancreatic Ductal Adenocarcinoma

Rong Zhou, Stephen Pickup, Hoon Choi, 2018, Clinical Cancer Research.

MODUL—a multicenter randomized clinical trial of biomarker-driven maintenance therapy following first-line standard induction treatment of metastatic colorectal cancer: an adaptable signal-seeking approach

E. Van Cutsem, M. Ducreux, J. Tabernero, 2018, Journal of Cancer Research and Clinical Oncology.

NCI-MATCH (Molecular Analysis for Therapy Choice) – a national signal finding trial.

R. Gray, K. Flaherty, L. Rubinstein, 2016 .

Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis.

R. Ozols, P. Engstrom, S. Litwin, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I clinical and pharmacokinetic study of the new topoisomerase inhibitor GI147211 given as a 72-h continuous infusion.

L. Paz-Ares, P. O'dwyer, S. Kaye, 1998, British Journal of Cancer.

Abstract B080: Update on the NCI-Molecular Analysis for Therapy Choice (NCI-MATCH/EAY131) precision medicine trial

R. Gray, A. Iafrate, J. Sklar, 2018 .

Pharmacokinetic study of trimetrexate in combination with cisplatin.

S. Litwin, P. O'dwyer, G. Hudes, 1991, Cancer research.

Pyrazole: preclinical reassessment

B. Leyland-Jones, P. O'dwyer, J. Plowman, 1988, Investigational New Drugs.

Monoclonal antibodies in the treatment of colorectal cancer.

P. O'dwyer, M. L. Veronese, 2004, European journal of cancer.

Phase I trial of UFT/leucovorin and irinotecan in patients with advanced cancer.

C. Thorn, D. Haller, P. O'dwyer, 2004, European journal of cancer.

Phase I clinical and pharmacogenetic trial of irinotecan and raltitrexed administered every 21 days to patients with cancer.

L. Kluijtmans, D. Haller, P. O'dwyer, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH)

David J. Sims, R. Gray, A. Iafrate, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Combination Paclitaxel and Palbociclib: Results of a Phase I Trial in Advanced Breast Cancer

A. Troxel, M. Feldman, M. Rosen, 2019, Clinical Cancer Research.

Initial report on intravesical administration of N-trifluoroacetyladriamycin-14-valerate (AD 32) to patients with refractory superficial transitional cell carcinoma of the urinary bladder.

R. Bahnson, G. Steinberg, P. O'dwyer, 1997, Urology.

Initial report on intraves1cal administration of N-trifluoroacetyladriamycin-14-valerate (AD 32) to patients with refractory superficial transitional cell carcinoma of the urinary bladder

R. Bahnson, G. Steinberg, P. O'dwyer, 1997 .

A phase I dose escalation trial of nab-paclitaxel and fixed dose radiation in patients with unresectable or borderline resectable pancreatic cancer

J. Metz, P. O'dwyer, R. Mick, 2018, Cancer Chemotherapy and Pharmacology.

Phase II study of weekly 5-fluorouracil, cisplatin and vinblastine in advanced non-small cell lung cancer.

S. Litwin, P. O'dwyer, C. Langer, 1991, European journal of cancer.

MAX2--a convenient index to estimate the average per patient risk for chemotherapy toxicity; validation in ECOG trials.

M. Bonetti, A. Benson, G. Sledge, 2004, European journal of cancer.

Phase 2 study of treatment selection based on tumor thymidylate synthase expression in previously untreated patients with metastatic colorectal cancer: A trial of the ECOG‐ACRIN Cancer Research Group (E4203)

P. Catalano, A. Benson, J. Grem, 2018, Cancer.

Abstracts reprinted from Journal of Clinical Oncology

S. Lipsitz, A. Benson, E. Guadagnoli, 2002, Annals of Surgical Oncology.

Cisplatin, carboplatin, and cyclophosphamide combination chemotherapy in advanced-stage ovarian carcinoma: an Eastern Cooperative Oncology Group pilot study.

J. Grem, P. O'dwyer, D. Trump, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Axillary dissection in primary breast cancer.

P. O'dwyer, 1991, BMJ.

Effect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor: NCI-MATCH Subprotocol EAY131-Y Nonrandomized Trial.

Carlos L. Arteaga, R. Gray, K. Flaherty, 2020, JAMA oncology.

Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Results of the NCI-MATCH Trial Subprotocol H.

R. Gray, K. Flaherty, L. Rubinstein, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Early treatment-related neutropenia predicts response to palbociclib

A. Troxel, A. DeMichele, G. Schwartz, 2020, British Journal of Cancer.

Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W.

R. Gray, K. Flaherty, P. Hammerman, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design

David J. Sims, R. Gray, A. Iafrate, 2020, Journal of the National Cancer Institute.

Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors

G. Shapiro, R. Prinjha, I. Braña, 2019, JNCI cancer spectrum.

Nab-Paclitaxel and Gemcitabine as First-line Treatment of Advanced or Metastatic Cholangiocarcinoma: A Phase 2 Clinical Trial

P. Catalano, A. Benson, P. O'dwyer, 2018, JAMA oncology.

The present and future of angiogenesis-directed treatments of colorectal cancer.

P. O'dwyer, 2006, The oncologist.

Phase I/pharmacokinetic reevaluation of thioTEPA.

P. Engstrom, S. Litwin, P. O'dwyer, 1991, Cancer research.

Phase I study of thiotepa in combination with the glutathione transferase inhibitor ethacrynic acid.

R. Ozols, K. Tew, S. Litwin, 1991, Cancer Research.

FG-3019, A Human Monoclonal Antibody to Connective Tissue Growth Factor, Combined with Chemotherapy in Patients with Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma

A. Koong, S. Hemmerich, A. Giaccia, 2016 .

Locally advanced pancreatic cancer: maybe not so local.

P. O'dwyer, 2016, The Lancet. Oncology.

Priorities in colorectal cancer research: recommendations from the Gastrointestinal Scientific Leadership Council of the Coalition of Cancer Cooperative Groups.

Jeffery T. Sloan, D. Sargent, N. Petrelli, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Role of Jun and Jun kinase in resistance of cancer cells to therapy.

P. O'dwyer, I. Vasilevskaya, 2003, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

Gonadotropin hormone-releasing hormone analogues: a new therapeutic approach for prostatic carcinoma.

P. O'dwyer, M. Eisenberger, M. Friedman, 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Disruption of Signaling through SEK1 and MKK7 Yields Differential Responses in Hypoxic Colon Cancer Cells Treated with Oxaliplatin

P. O'dwyer, M. Selvakumaran, I. Vasilevskaya, 2008, Molecular Pharmacology.

Comparative Effectiveness of Proton vs Photon Therapy as Part of Concurrent Chemoradiotherapy for Locally Advanced Cancer.

J. Metz, Ying Xiao, P. O'dwyer, 2019, JAMA oncology.

Resection of focally progressive gastrointestinal stromal tumours resistant to imatinib therapy.

P. O'dwyer, E. H. Wong, G. Tse, 2012, The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland.

Intergroup randomized phase III study of postoperative oxaliplatin, 5-fluorouracil and leucovorin (mFOLFOX6) vs mFOLFOX6 and bevacizumab (Bev) for patients (pts) with stage II/ III rectal cancer receiving pre-operative chemoradiation.

P. Catalano, A. Benson, N. Petrelli, 2016 .

Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain Metastases

K. Flaherty, M. Atkins, A. Troxel, 2009, Clinical Cancer Research.

Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203.

P. Catalano, A. Benson, P. O'dwyer, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mechanisms of hypertension associated with BAY 43-9006.

K. Flaherty, R. Townsend, P. O'dwyer, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pharmacokinetics of the chemopreventive agent oltipraz and of its metabolite M3 in human subjects after a single oral dose.

P. O'dwyer, J. Gallo, P. B. Laub, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Two phase I studies of concurrent radiation therapy with continuous-infusion 5-fluorouracil plus epirubicin, and either cisplatin or irinotecan for locally advanced upper gastrointestinal adenocarcinomas

J. Metz, D. Haller, P. O'dwyer, 2011, Cancer Chemotherapy and Pharmacology.

Differential Gene Expression Patterns and Interaction Networks in BCR/ABL Positive and Negative Adult Acute Lymphoblastic Leukemias.

D. Juric, B. Sikic, P. O'dwyer, 2006 .

A phase Ib/II study of the anti-CD47 antibody magrolimab with cetuximab in solid tumor and colorectal cancer patients.

J. Hecht, P. Philip, C. Takimoto, 2020 .

MRI assessment of early tumor response in metastatic renal cell carcinoma patients treated with sorafenib.

K. Flaherty, H. Kang, D. Heitjan, 2013, AJR. American journal of roentgenology.

Phase I study of GW572016 (lapatinib), a dual kinase inhibitor, in combination with irinotecan (IR), 5-fluorouracil (FU) and leucovorin (LV)

David A. Smith, D. Kerr, K. Flaherty, 2005 .

Phase I/pharmacokinetic/biochemical study of the nitroimadazole hypoxic cell sensitiser SR2508 (etanidazole) in combination with cyclophosphamide.

S. Litwin, P. O'dwyer, F. LaCreta, 1993, British Journal of Cancer.

P. Engstrom, S. Litwin, P. O'dwyer, 1991 .

Phase I and pharmacokinetic study of the novel platinum analogue CI-973 on a 5-daily dose schedule.

P. O'dwyer, G. Hudes, R. Schilder, 1992, Cancer research.

Phase I trial of 5-fluorouracil, leucovorin, and cisplatin in combination

M. Cornfeld, P. O'dwyer, R. Comis, 2004, Cancer Chemotherapy and Pharmacology.

Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil, and Leucovorin Versus Oxaliplatin, 5-Fluorouracil, Leucovorin, and Bevacizumab for Patients with Stage II or III Rectal Cancer Receiving Preoperative Chemoradiation: A Trial of the ECOG-ACRIN Research Group (E5204).

P. Catalano, N. Petrelli, J. Sloan, 2019, The oncologist.

Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly.

R. Ozols, P. O'dwyer, G. Hudes, 1994, Cancer research.

What happened to the US cancer cooperative groups? A status update ten years after the Institute of Medicine report

W. Curran, M. Schnall, M. Bertagnolli, 2020, Cancer.

Clinical, pharmacokinetic and biological studies of topotecan

P. O'dwyer, T. Halbherr, K. Yao, 2004, Cancer Chemotherapy and Pharmacology.

Teniposide: a review of 12 years of experience.

B. Leyland-Jones, S. Marsoni, P. O'dwyer, 1984, Cancer treatment reports.

Evaluation of carboplatin pharmacokinetics in the absence and presence of paclitaxel.

C. Obasaju, R. Ozols, P. O'dwyer, 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase I trial of the cryptophycin analogue LY355703 administered as an intravenous infusion on a day 1 and 8 schedule every 21 days.

P. O'dwyer, D. Vaughn, L. Schuchter, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase I and Pharmacokinetic Study of the Cytotoxic Ether Lipid Ilmofosine Administered by Weekly Two-Hour Infusion in Patients with Advanced Solid Tumors

P. O'dwyer, B. Giantonio, J. Mcphillips, 2004, Clinical Cancer Research.

Phase I trial of ilmofosine as a 24 hour infusion weekly

M. Mehren, P. O'dwyer, R. Schilder, 2004, Investigational New Drugs.

Phase I study of the novel taxane CT-2103 in patients with advanced solid tumors

M. Morgan, K. Flaherty, P. O'dwyer, 2005, Cancer Chemotherapy and Pharmacology.

Reversal of cisplatin resistance in human ovarian cancer cell lines by a c-jun antisense oligodeoxynucleotide (ISIS 10582): evidence for the role of transcription factor overexpression in determining resistant phenotype.

P. O'dwyer, K. Yao, B. Monia, 2002, Biochemical pharmacology.

Phase II trial of topotecan in advanced pancreatic cancer

P. Engstrom, P. O'dwyer, M. Simmonds, 1993 .

Sorafenib in Combination with Oxaliplatin, Leucovorin, and Fluorouracil (Modified FOLFOX6) as First-line Treatment of Metastatic Colorectal Cancer: The RESPECT Trial

R. Salazar, E. Van Cutsem, J. Tabernero, 2013, Clinical Cancer Research.

Phase I and pharmacokinetic trial of the novel taxane BMS-184476 administered as a 1-hour intravenous infusion in combination with cisplatin every 21 days.

D. Haller, P. O'dwyer, D. Vaughn, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase I trial of etoposide, doxorubicin and cisplatin (EAP) in combination with GM-CSF.

S. Arbuck, P. O'dwyer, L. Miller, 1996, European journal of cancer.

Trimetrexate: a new antifol entering clinical trials

B. Leyland-Jones, P. O'dwyer, J. Plowman, 2004, Investigational New Drugs.

Phase I/II study of mocetinostat in combination with gemcitabine for patients with advanced pancreatic cancer and other advanced solid tumors

D. Potvin, H. Hurwitz, E. Chan, 2018, Cancer Chemotherapy and Pharmacology.

Value of biopsy in the assessment of a retroperitoneal mass.

P. O'dwyer, R. Reid, C. Chew, 2006, The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland.

Association of severe and fatal infections and treatment with pentostatin.

S. Marsoni, P. O'dwyer, A. Spiers, 1986, Cancer treatment reports.

A phase I and pharmacokinetic study of tallimustine [PNU 152241 (FCE 24517)] in patients with advanced cancer.

G. Weiss, D. V. Von Hoff, P. O'dwyer, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Patient treatment on a compassionate basis: documentation of high adverse drug reaction rate.

B. Leyland-Jones, P. O'dwyer, D. Macfarlane, 1992, Annals of oncology : official journal of the European Society for Medical Oncology.

Toxicity study of gemcitabine, oxaliplatin, and bevacizumab, followed by 5-fluorouracil, oxaliplatin, bevacizumab, and radiotherapy, in patients with locally advanced pancreatic cancer

G. Ginsberg, D. Heitjan, M. Feldman, 2013, Cancer Chemotherapy and Pharmacology.

Dabrafenib and trametinib in patients with tumors with BRAF V600E/K mutations: Results from the molecular analysis for therapy choice (MATCH) Arm H.

R. Gray, K. Flaherty, L. Rubinstein, 2019, Journal of Clinical Oncology.

Chronic dosing of oltipraz in people at increased risk for colorectal cancer.

P. Engstrom, S. Litwin, P. O'dwyer, 2001, Cancer detection and prevention.

Association between VEGF Splice Isoforms and Progression-Free Survival in Metastatic Colorectal Cancer Patients Treated with Bevacizumab

P. Catalano, S. Harper, D. Bates, 2012, Clinical Cancer Research.

Effects of bortezomib (PS-341) on NF-κB activation in peripheral blood mononuclear cells (PBMCs) of advanced non-small lung cancer (NSCLC) patients: A phase II/pharmacodynamic trial

Steven W. Johnson, P. O'dwyer, I. Vasilevskaya, 2004 .

Stereoselective pharmacokinetics of L-buthionine SR-sulfoximine in patients with cancer.

R. Ozols, P. O'dwyer, T. Hamilton, 1994, Drug metabolism and disposition: the biological fate of chemicals.

A phase II trial of gemcitabine, irinotecan and panitumumab in advanced cholangiocarcinoma.

A. Sepulveda, P. O'dwyer, T. Uehara, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I combination trial of gemcitabine, paclitaxel, and carboplatin in patients with advanced malignancy

K. Flaherty, S. Hahn, P. O'dwyer, 2003, Cancer Chemotherapy and Pharmacology.

Schedule as a determinant of cytotoxic drug activity.

P. O'dwyer, R. Comis, 1989, Current opinion in oncology.

Platinum analogues in preclinical and clinical development

R. Ozols, P. O'dwyer, T. Hamilton, 1993, Current opinion in oncology.

Ado-trastuzumab emtansine (T-DM1) in patients (pts) with HER2 amplified (amp) tumors excluding breast and gastric/gastro-esophageal junction (GEJ) adenocarcinomas: Results from the National Cancer Institute (NCI) Molecular Analysis for Therapy Choice (MATCH) trial.

S. Luoh, R. Gray, K. Flaherty, 2018 .

Flavone acetic acid (LM 975, NSC 347512) A novel antitumor agent

B. Leyland-Jones, P. O'dwyer, F. Valeriote, 2004, Cancer Chemotherapy and Pharmacology.

Exploratory biomarker findings from cohort 2 of MODUL: An adaptable, phase 2, signal-seeking trial of fluoropyrimidine + bevacizumab ± atezolizumab maintenance therapy for BRAFwt metastatic colorectal cancer.

E. Van Cutsem, M. Ducreux, J. Tabernero, 2021 .

Phase I trial of the antifolate ZD9331 in combination with cisplatin in patients with refractory solid malignancies

K. Flaherty, D. Haller, P. O'dwyer, 2004, Cancer Chemotherapy and Pharmacology.

Abstract CT124: A phase Ib/II study of BMS-813160, a CC chemokine receptor (CCR) 2/5 dual antagonist, in combination with chemotherapy or nivolumab in patients (pts) with advanced pancreatic or colorectal cancer

H. Lenz, M. Pishvaian, P. O'dwyer, 2018, Clinical Trials.

A phase II/III study of perioperative nivolumab and ipilimumab in patients (pts) with locoregional esophageal (E) and gastroesophageal junction (GEJ) adenocarcinoma: Results of a safety run-in—A trial of the ECOG-ACRIN Cancer Research Group (EA2174).

C. Gatsonis, P. Catalano, A. Benson, 2021 .

Phase I trial of the thymidylate synthase inhibitor AG331 as a 5-day continuous infusion.

P. O'dwyer, J. Gallo, A. Johnston, 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

A randomized double-blind study of gallium nitrate compared with etidronate for acute control of cancer-related hypercalcemia.

R. Warrell, P. O'dwyer, G. Heller, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Quantitative effects on c-Jun N-terminal protein kinase signaling determine synergistic interaction of cisplatin and 17-allylamino-17-demethoxygeldanamycin in colon cancer cell lines.

P. O'dwyer, I. Vasilevskaya, T. Rakitina, 2004, Molecular Pharmacology.

Geldanamycin and its 17-allylamino-17-demethoxy analogue antagonize the action of Cisplatin in human colon adenocarcinoma cells: differential caspase activation as a basis for interaction.

P. O'dwyer, I. Vasilevskaya, T. Rakitina, 2003, Cancer research.

Phase II trial of autophagy inhibition using hydroxychloroquine (HCQ) with FOLFOX/bevacizumab in the first-line treatment of advanced colorectal cancer.

D. Heitjan, M. Rosen, P. O'dwyer, 2015 .

Anaphylactic reactions to diaziquone.

P. O'dwyer, D. Hoth, J. G. Posada, 1984, Cancer treatment reports.

A Phase II trial of weekly infusional 5-fluorouracil in combination with lowdose leucovorin in patients with advanced colorectal cancer

R. Ozols, L. Weiner, P. O'dwyer, 2004, Investigational new drugs.

Erratum to: Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (Autophagy, 12, 1, 1-222, 10.1080/15548627.2015.1100356

Sara W. Bird, Erinna F. Lee, Michael D. Kim, 2016 .

Phase II trial of thio-TEPA in relapsed and refractory ovarian carcinoma.

P. O'dwyer, C. Langer, N. Rosenblum, 1991, Gynecologic oncology.

Effect of BRAFV600E on response to sorafenib in advanced thyroid cancer patients.

A. Chalian, K. Flaherty, A. Troxel, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Molecular analysis for therapy choice (MATCH) arm W: Phase II study of AZD4547 in patients with tumors with aberrations in the FGFR pathway.

R. Gray, K. Flaherty, L. Harris, 2018 .

Biochemical changes associated with a multidrug-resistant phenotype of a human glioma cell line with temozolomide-acquired resistance.

Karin Reed, M. Murphy, P. O'dwyer, 2002, Biochemical pharmacology.

Determinants of cisplatin sensitivity in normal versus spontaneously transformed rat ovarian surface epithelial cells.

R. Perez, P. O'dwyer, S. Johnson, 1995, Gynecologic oncology.

Comparative Effectiveness of Total Neoadjuvant Therapy Versus Standard Adjuvant Chemotherapy for Locally Advanced Rectal Cancer.

O. Margalit, P. O'dwyer, K. Reiss, 2021, Clinical colorectal cancer.

Alpha-interferon does not increase the efficacy of 5-fluorouracil in advanced colorectal cancer

M. Buyse, A. Piga, C. Köhne, 2001, British Journal of Cancer.

Phase I study of nivolumab (nivo) + nab-paclitaxel (nab-P) ± gemcitabine (Gem) in solid tumors: Interim results from the pancreatic cancer (PC) cohorts.

E. Kwak, Z. Wainberg, P. O'dwyer, 2017 .

Chromatographic analysis of methylmercaptopurine riboside in human plasma and urine.

P. O'dwyer, F. LaCreta, P. Tinsley, 1991, Journal of chromatography.

PHASE II TRIAL OF PACLITAXEL IN PATIENTS WITH ADVANCED COLON CANCER PREVIOUSLY UNTREATED WITH CYTOTOXIC CHEMOTHERAPY: AN EASTERN COOPERATIVE ONCOLOGY GROUP TRIAL (PA286)

L. Grochow, D. Neuberg, N. Petrelli, 1996, American journal of therapeutics.

Updated efficacy of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal cancer (mCRC).

C. Atreya, J. Schellens, J. Tabernero, 2015 .

MGCD265, an oral Met/VEGFR multitargeted receptor tyrosine kinase inhibitor, in combination with erlotinib: Phase I clinical experience.

M. Mehran, A. Tolcher, K. Papadopoulos, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of the autophagy inhibitor hydroxychloroquine with FOLFOX and bevacizumab in front line treatment of metastatic colorectal cancer.

A. Troxel, D. Heitjan, M. Rosen, 2017 .

Acute Toxicity of Proton Versus Photon Chemoradiation Therapy for Pancreatic Adenocarcinoma: A Cohort Study

J. Metz, P. O'dwyer, R. Mick, 2013 .

Design and development of the molecular analysis for Therapy Choice (NCI-MATCH) Designated Laboratory Network.

A. Iafrate, J. Sklar, K. Flaherty, 2019, Journal of Clinical Oncology.

Biochemical modulation of 5-fluorouracil by PALA.

P. O'dwyer, 1990, Cancer Investigation.

Trimetrexate: clinical development of a nonclassical antifolate.

B. Leyland-Jones, P. O'dwyer, D. Hoth, 1987, NCI monographs : a publication of the National Cancer Institute.

Phase II pharmacodynamic trial of palbociclib in patients with KRAS mutant colorectal cancer.

Christine E. Edmonds, D. Mankoff, M. Feldman, 2015 .

Quantitation of 5-fluorouracil catabolism in human liver in vivo by three-dimensional localized 19F magnetic resonance spectroscopy.

T. Brown, P. O'dwyer, W. Negendank, 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

51LBA Completion of a Phase II study of sorafenib for advanced thyroid cancer

A. Chalian, A. Troxel, S. Mandel, 2009 .

Intraperitoneal cisplatin and etoposide in peritoneal mesothelioma: favorable outcome with a multimodality approach

P. O'dwyer, C. Langer, R. Catalano, 2004, Cancer Chemotherapy and Pharmacology.

Aggressive Supportive Care Improves Outcomes in the Combined Modality Treatment of Pancreatic and Duodenal Cancer

E. Rosato, M. Hampshire, J. Metz, 2007 .

Bowel perforation and fistula formation in colorectal cancer patients treated on Eastern Cooperative Oncology Group (ECOG) studies E2200 and E3200.

H X Chen, P. Catalano, A. Benson, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the Eastern Cooperative Oncology Group study E2200.

P. Catalano, A. Benson, P. O'dwyer, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Pharmacokinetic analysis and pharmacodynamic evidence of autophagy inhibition in patients with newly diagnosed glioblastoma treated on a phase I trial of hydroxychloroquine in combination with adjuvant temozolomide and radiation (ABTC 0603).

T. Mikkelsen, S. Brem, P. O'dwyer, 2010 .

InterAACT: An international multicenter open label randomized phase II advanced anal cancer trial comparing cisplatin (CDDP) plus 5-fluorouracil (5-FU) versus carboplatin (CBDCA) plus weekly paclitaxel (PTX) in patients with inoperable locally recurrent (ILR) or metastatic disease.

J. Welch, A. Benson, D. Cunningham, 2015 .

Comparative cytotoxicity of CI‐973, cisplatin, carboplatin and tetraplatin in human ovarian carcinoma cell lines

R. Ozols, R. Perez, P. O'dwyer, 1991, International Journal of Cancer.

Population pharmacokinetic (PPK) analysis of recombinant human Apo2L/TRAIL (rhApo2L/TRAIL) in a Phase 1a Study in advanced cancer and lymphoma

R. Herbst, W. Novotny, P. O'dwyer, 2008 .

Effects of bortezomib (PS-341) on NF-κB activation in peripheral blood mononuclear cells (PBMCs) of advanced non-small lung cancer (NSCLC) patients: A phase II/pharmacodynamic trial.

P. O'dwyer, I. Vasilevskaya, S. Johnson, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomized phase II trial of niraparib plus either nivolumab or ipilimumab in patients with advanced pancreatic cancer whose cancer has not progressed on platinum-based therapy.

D. Mankoff, K. Nathanson, S. Domchek, 2019, Journal of Clinical Oncology.

Phase I and Pharmacokinetic Trial of the Proapoptotic Sulindac Analog CP-461 in Patients with Advanced Cancer 1

D. Haller, P. O'dwyer, J. Gallo, 2002 .

The terrible choice: re-evaluating hospice eligibility criteria for cancer.

D. Asch, M. Naylor, F. Barg, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract CT139: NCI Molecular Analysis for Therapy Choice (NCI-MATCH EAY131) arm B: Phase II study of afatinib in patients (pts) with HER2 (ERBB2) activating mutations

R. Gray, K. Flaherty, L. Harris, 2019, Clinical Trials.

A phase II trial of an oral CDK 4/6 inhibitor, PD0332991, in advanced breast cancer.

D. Heitjan, M. Feldman, A. DeMichele, 2013 .

ECOG E3201: Intergroup randomized phase III study of postoperative irinotecan, 5- fluorouracil (FU), leucovorin (LV) (FOLFIRI) vs oxaliplatin, FU/LV (FOLFOX) vs FU/LV for patients (pts) with stage II/ III rectal cancer receiving either pre or postoperative radiation (RT)/ FU.

A. Benson, F. Sinicrope, R. Mayer, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Follow-up of stage B and C colorectal cancer in the United States and France.

D. Haller, P. O'dwyer, J. Stevenson, 2001, Seminars in oncology.

A phase II study of high-dose bevacizumab in combination with irinotecan , 5-fluorouracil , leucovorin , as initial therapy for advanced colorectal cancer : results from the eastern cooperative oncology group study E 2200

P. Catalano, A. Benson, P. O'dwyer, 2006 .

Phase 1 trial of gemcitabine/nab-paclitaxel in combination with the autophagy inhibitor hydroxychloroquine in previously untreated patients with metastatic pancreatic adenocarcinoma.

V. Velculescu, D. Heitjan, P. O'dwyer, 2015 .

A Phase I Study of an Agonist CD40 Monoclonal Antibody (CP-870,893) in Combination with Gemcitabine in Patients with Advanced Pancreatic Ductal Adenocarcinoma

A. Alavi, D. Torigian, A. Troxel, 2013, Clinical Cancer Research.

Phase II/pharmacodynamic trial of PD0332991 in patients with breast, colon, germ cell, and epithelial tumors containing amplification of CCND1.

J. Christensen, A. DeMichele, P. O'dwyer, 2011, Journal of Clinical Oncology.

Paclitaxel and carboplatin in the treatment of advanced non-small cell lung cancer.

R. Ozols, P. O'dwyer, R. Comis, 1995, Seminars in oncology.

LBA-10MODUL – A Multicentre Randomised Clinical Trial of Biomarker-Driven Therapy for the 1st-Line Maintenance Treatment of Metastatic Colorectal Cancer (mCRC): A Highly Adaptable Signal-Seeking Approach

M. Ducreux, A. Grothey, P. O'dwyer, 2015 .

Clinical Status of Cisplatin, Carboplatin, and Other Platinum‐Based Antitumor Drugs

Steven W. Johnson, P. O'dwyer, J. Stevenson, 2006 .

Phase I trial of 5-fluorouracil by 24-hour infusion weekly

R. Ozols, P. O'dwyer, G. Hudes, 1993, Investigational New Drugs.

FG-3019, a human monoclonal antibody to CTGF, with gemcitabine/erlotinib in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma.

A. Koong, A. Giaccia, C. Lopez, 2013 .

Race, treatment preferences, and hospice enrollment: Eligibility criteria may exclude patients with the greatest needs for care

D. Asch, P. O'dwyer, D. Casarett, 2009, Cancer.

Differential gene expression patterns and interaction networks in BCR-ABL-positive and -negative adult acute lymphoblastic leukemias.

D. Juric, B. Sikic, P. O'dwyer, 2006, Journal of Clinical Oncology.

CDK 4/6 Inhibitor Palbociclib (PD0332991) in Rb+ Advanced Breast Cancer: Phase II Activity, Safety, and Predictive Biomarker Assessment

D. Heitjan, M. Feldman, M. Rosen, 2014, Clinical Cancer Research.

Phase I/pharmacokinetic trial of the novel thioxanthone SR233377 (WIN33377) on a 5-day schedule

P. O'dwyer, J. Stevenson, M. Graham, 1999, Cancer Chemotherapy and Pharmacology.

Disruption of Signaling through SEK1 and MKK7 Yields Differential Responses in Hypoxic Colon Cancer Cells Treated with Oxaliplatin

P. O'dwyer, M. Selvakumaran, I. Vasilevskaya, 2008, Molecular Pharmacology.

Pharmakokinetics and bioavailability study of ethacrynic acid as a modulator of drug resistance in patients with cancer.

K. Tew, P. O'dwyer, F. LaCreta, 1994, The Journal of pharmacology and experimental therapeutics.

A phase 2 study of defactinib (VS-6063) in patients with NF2 altered tumors: Results from NCI-match (EAY131) subprotocol U.

R. Gray, M. Zauderer, K. Flaherty, 2021 .

Evidence for improved pathologic complete response (PCR) rate after preoperative chemoradiotherapy with 5-FU/oxaliplatin (5FU/OX) for rectal cancer.

J. Metz, L. Solin, D. Haller, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II study: Combination of sorafenib with docetaxel and cisplatin in the treatment of metastatic or advanced unresectable gastric and gastroesophageal junction (GEJ) adenocarcinoma (ECOG 5203)

A. Benson, P. O'dwyer, Weijing Sun, 2008 .